2014 was an exciting year in the fields of HIV and viral hepatitis, highlighted by growing awareness and promising new data for HIV pre-exposure prophylaxis (PrEP) and approval of highly effective new interferon-free combination pills for hepatitis C. But there were also some setbacks and challenges, including disappointments in HIV cure research and the high cost of the new hepatitis C drugs.
HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.
Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.